Unlike canakinumab, which selectively inhibits IL-1β, the anti-inflammatory properties of colchicine involve multiple cellular and molecular mechanisms, and the use of small doses of colchicine reduces the composite risk of CV death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization in patients with CAD (100). This evidence concerns the gene IL1B and myocardial infarction.